Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis
Authors:
- 1 May 2014
- journal article
- review article
- Published by Elsevier in Psychosomatics
- Vol. 55 (3) , 221-234
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV‐infected, evaluated patientsAlimentary Pharmacology & Therapeutics, 2013
- Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statementJournal of Hepatology, 2012
- Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2011
- Immune system to brain signaling: Neuropsychopharmacological implicationsPharmacology & Therapeutics, 2011
- Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot StudyDigestive Diseases and Sciences, 2007
- The Medical Management of DepressionNew England Journal of Medicine, 2005
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJournal of Hepatology, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979